Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children

Exclusion Criteria

• •Ipratropium bromide received within four hours before admission
• •First acute asthmatic attack
• •Hospital admission to intensive care with asthma within six months before inclusion
• •Hospital admission for asthma during the month prior to inclusion
• •Corticosteroid-dependent asthma (oral corticosteroid therapy) or recently stopped corticosteroid therapy
• •Concomitant cardiac disease
• •Life threatening disease requiring immediate management; including: silent chest on auscultation, cyanosis, bradycardia less than 60 beats/min (bpm), confusion, coma
• •Hypersensitivity to ipratropium bromide, salbutamol, or to any of their excipients
• •Renal or hepatic insufficiency
• •Poorly controlled diabetes
• •Patients suffering from a disease considered to be severe by the investigator and which, in the opinion of the investigator, could interfere or invalidate the measurements performed in the trial
• •Past history of lung surgery
• •Major respiratory disease: pulmonary fibrosis, bronchiectasis, sarcoidosis, tuberculosis, respiratory disease due to AIDS, cystic fibrosis
• •Patients unable to follow with protocol or correctly undergo the evaluations
• •Patients who are taking part in another clinical trial during this trial or who have done so within the month before the trial
• •Previous participation in this trial